Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 410

1.

Adherence to Treat-to-Target Management in Rheumatoid Arthritis and Associated Factors: Data from the International RA BIODAM Cohort.

Sepriano A, Ramiro S, FitzGerald O, Østergaard M, Homik J, van der Heijde D, Elkayam O, Thorne C, Larché MJ, Ferraccioli G, Backhaus M, Burmester GR, Boire G, Combe B, Saraux A, Dougados M, Rossini M, Govoni M, Sinigaglia L, Cantagrel A, Barnabe C, Bingham CO 3rd, Tak PP, van Schaardenburg D, Hammer HB, Paschke J, Dadashova R, Hutchings E, Landewé R, Maksymowych WP.

J Rheumatol. 2019 Sep 15. pii: jrheum.190303. doi: 10.3899/jrheum.190303. [Epub ahead of print]

PMID:
31523049
2.

The International RA BIODAM Cohort for Validation of Soluble Biomarkers in Rheumatoid Arthritis: Cohort Description.

Maksymowych WP, FitzGerald O, Østergaard M, Homik J, van der Heijde D, Lambert RG, Elkayam O, Ramiro S, Thorne C, Larché MJ, Ferraccioli G, Backhaus M, Burmester GR, Boire G, Combe B, Saraux A, Dougados M, Rossini M, Govoni M, Sinigaglia L, Cantagrel A, Allaart R, Barnabe C, Bingham CO 3rd, Tak PP, van Schaardenburg D, Hammer HB, Paschke J, Dadashova R, Hutchings E, Sepriano A, Landewé R.

J Rheumatol. 2019 Sep 1. pii: jrheum.190302. doi: 10.3899/jrheum.190302. [Epub ahead of print]

PMID:
31474600
3.

Chlorhexidine Inefficacy in Ventilated Patients: Reply.

La Combe B, Ricard JD.

Anesthesiology. 2019 Oct;131(4):939-940. doi: 10.1097/ALN.0000000000002926. No abstract available.

PMID:
31403495
4.

The Reference Site Collaborative Network of the European Innovation Partnership on Active and Healthy Ageing.

Bousquet J, Illario M, Farrell J, Batey N, Carriazo AM, Malva J, Hajjam J, Colgan E, Guldemond N, Perälä-Heape M, Onorato GL, Bedbrook A, Leonardini L, Stroetman V, Birov S, Abreu C, Abrunhosa A, Agrimi A, Alalääkkölä T, Allegretti N, Alonso-Trujillo F, Álvarez-Benito M, Angioli S, Apóstolo J, Armitage G, Arnavielhe S, Baena-ParejoI M, Bamidis PD, Balenović A, Barbolini M, Baroni I, Blain H, Bernard PL, Bersani M, Berti E, Bogatyrchuk L, Bourret R, Brehm J, Brussino L, Buhr D, Bultje D, Cabeza E, Cano A, De Capitani C, Carantoña E, Cardoso A, Coll Clavero JI, Combe B, Conforti D, Coppola L, Corti F, Coscioni E, Costa E, Crooks G, Cunha A, Daien C, Dantas, Darpón Sierra J, Davoli M, Dedeu Baraldes A, De Luca V, De Nardi L, Di Ciano M, Dozet A, Ekinci B, Erve S, Espinoza Almendro JM, Fait A, Fensli R, Fernandez Nocelo S, Gálvez-Daza P, Gámez-Payá J, García Sáez M, Garcia Sanchez I, Gemicioğlu B, Goetzke W, Goossens E, Geurdens M, Gütter Z, Hansen H, Hartman S, Hegendörfer G, Heikka H, Henderson D, Héran D, Hirvonen S, Iaccarino G, Jansson N, Kallasvaara H, Kalyoncu F, Kirchmayer U, Kokko JA, Korpelainen J, Kostka T, Kuna P, Lajarín Ortega T, Lama CM, Laune D, Lauri D, Ledroit V, Levato G, Lewis L, Liotta G, Lundgren L, Lupiañez-Villanueva F, Mc Garry P, Maggio M, Manuel de Keenoy E, Martinez C, Martínez-Domene M, Martínez-Lozano Aranaga B, Massimilliano M, Maurizio A, Mayora O, Melle C, Mendez-Zorilla A, Mengon H, Mercier G, Mercier J, Meyer I, Millet Pi-Figueras A, Mitsias P, Molloy DW, Monti R, Moro ML, Muranko H, Nalin M, Nobili A, Noguès M, O'Caoimh R, Pais S, Papini D, Parkkila P, Pattichis C, Pavlickova A, Peiponen A, Pereira S, Pépin JL, Piera Jiménez J, Portheine P, Potel L, Pozzi AC, Quiñonez P, Ramirez Lauritsen X, Ramos MJ, Rännäli-Kontturi A, Risino A, Robalo-Cordeiro C, Rolla G, Roller R, Romano M, Romano V, Ruiz-Fernández J, Saccavini C, Sachinopoulou A, Sánchez Rubio MJ, Santos L, Scalvini S, Scopetani E, Smedberg D, Solana-Lara R, Sołtysik B, Sorlini M, Stericker S, Stramba Badiale M, Taillieu I, Tervahauta M, Teixeira A, Tikanmäki H, Todo-Bom A, Tooley A, Tuulonen A, Tziraki C, Ussai S, Van der Veen S, Venchiarutti A, Verdoy-Berastegi D, Verissimo M, Visconti L, Vollenbroek-Hutten M, Weinzerl K, Wozniak L, Yorgancıoğlu A, Zavagli V, Zurkuhlen AJ.

Transl Med UniSa. 2019 Jan 6;19:66-81. eCollection 2019 Jan-Jun.

5.

Outcome of patients with early arthritis without rheumatoid factor and ACPA and predictors of rheumatoid arthritis in the ESPOIR cohort.

Mouterde G, Rincheval N, Lukas C, Daien C, Saraux A, Dieudé P, Morel J, Combe B.

Arthritis Res Ther. 2019 Jun 6;21(1):140. doi: 10.1186/s13075-019-1909-8.

6.

Shifting from a Rheumatologic Point of View toward Patient-centered Care in Rheumatoid Arthritis with an Integrated Management of Comorbidities.

Roubille C, Fesler P, Combe B.

J Rheumatol. 2019 Jun;46(6):545-547. doi: 10.3899/jrheum.181379. No abstract available.

PMID:
31154441
7.

Re-treatment with abatacept plus methotrexate for disease flare after complete treatment withdrawal in patients with early rheumatoid arthritis: 2-year results from the AVERT study.

Emery P, Burmester GR, Bykerk VP, Combe BG, Furst DE, Maldonado MA, Huizinga TW.

RMD Open. 2019 Feb 8;5(1):e000840. doi: 10.1136/rmdopen-2018-000840. eCollection 2019.

8.

Pneumonia-Specific Escherichia coli with Distinct Phylogenetic and Virulence Profiles, France, 2012-2014.

La Combe B, Clermont O, Messika J, Eveillard M, Kouatchet A, Lasocki S, Corvec S, Lakhal K, Billard-Pomares T, Fernandes R, Armand-Lefevre L, Bourdon S, Reignier J, Fihman V, de Prost N, Bador J, Goret J, Wallet F, Denamur E, Ricard JD; COLOCOLI group; COLOCOLI Group.

Emerg Infect Dis. 2019 Apr;25(4):710-718. doi: 10.3201/eid2504.180944.

9.

Efficacy and safety data based on historical or pre-existing conditions at baseline for patients with active rheumatoid arthritis who were treated with baricitinib.

Combe B, Balsa A, Sarzi-Puttini P, Tony HP, de la Torre I, Rogai V, Durand F, Witt S, Zhong J, Dougados M.

Ann Rheum Dis. 2019 Aug;78(8):1135-1138. doi: 10.1136/annrheumdis-2018-214261. Epub 2019 Mar 6. No abstract available.

10.

Correction to: On-drug and drug-free remission by baseline symptom duration: abatacept with methotrexate in patients with early rheumatoid arthritis.

Bykerk VP, Burmester GR, Combe BG, Furst DE, Huizinga TWJ, Ahmad HA, Emery P.

Rheumatol Int. 2019 May;39(5):945. doi: 10.1007/s00296-018-4232-9.

11.

Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study.

Gottenberg JE, Morel J, Perrodeau E, Bardin T, Combe B, Dougados M, Flipo RM, Saraux A, Schaeverbeke T, Sibilia J, Soubrier M, Vittecoq O, Baron G, Constantin A, Ravaud P, Mariette X; French Society of Rheumatology and the investigators participating in AIR, ORA, and REGATE registries.

BMJ. 2019 Jan 24;364:l67. doi: 10.1136/bmj.l67.

12.

Clinical and Structural Efficacy of Hydroxychloroquine in Rheumatoid Arthritis: A Systematic Review.

Rempenault C, Combe B, Barnetche T, Gaujoux-Viala C, Lukas C, Morel J, Hua C.

Arthritis Care Res (Hoboken). 2019 Jan 10. doi: 10.1002/acr.23826. [Epub ahead of print]

PMID:
30629341
13.

Oropharyngeal colonization: epidemiology, treatment and ventilator-associated pneumonia prevention.

Messika J, La Combe B, Ricard JD.

Ann Transl Med. 2018 Nov;6(21):426. doi: 10.21037/atm.2018.10.17. Review.

14.

Cardiovascular morbidity and mortality in primary Sjögren syndrome: a systematic review and meta-analysis.

Beltai A, Barnetche T, Daien C, Lukas C, Gaujoux-Viala C, Combe B, Morel J.

Arthritis Care Res (Hoboken). 2018 Dec 20. doi: 10.1002/acr.23821. [Epub ahead of print]

PMID:
30570824
15.

Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis.

Quistrebert J, Hässler S, Bachelet D, Mbogning C, Musters A, Tak PP, Wijbrandts CA, Herenius M, Bergstra SA, Akdemir G, Johannesson M, Combe B, Fautrel B, Chollet-Martin S, Gleizes A, Donnellan N, Deisenhammer F, Davidson J, Hincelin-Mery A, Dönnes P, Fogdell-Hahn A, De Vries N, Huizinga T, Abugessaisa I, Saevarsdottir S, Hacein-Bey-Abina S, Pallardy M, Broët P, Mariette X; ABIRISK Consortium.

Semin Arthritis Rheum. 2019 Jun;48(6):967-975. doi: 10.1016/j.semarthrit.2018.10.006. Epub 2018 Oct 12.

PMID:
30420245
16.

On-drug and drug-free remission by baseline symptom duration: abatacept with methotrexate in patients with early rheumatoid arthritis.

Bykerk VP, Burmester GR, Combe BG, Furst DE, Huizinga TWJ, Ahmad HA, Emery P.

Rheumatol Int. 2018 Dec;38(12):2225-2231. doi: 10.1007/s00296-018-4173-3. Epub 2018 Oct 20. Erratum in: Rheumatol Int. 2019 Feb 5;:.

17.

Update of French society for rheumatology recommendations for managing rheumatoid arthritis.

Daien C, Hua C, Gaujoux-Viala C, Cantagrel A, Dubremetz M, Dougados M, Fautrel B, Mariette X, Nayral N, Richez C, Saraux A, Thibaud G, Wendling D, Gossec L, Combe B.

Joint Bone Spine. 2019 Mar;86(2):135-150. doi: 10.1016/j.jbspin.2018.10.002. Epub 2018 Oct 10.

PMID:
30315988
18.

Oropharyngeal Bacterial Colonization after Chlorhexidine Mouthwash in Mechanically Ventilated Critically Ill Patients.

La Combe B, Mahérault AC, Messika J, Billard-Pomares T, Branger C, Landraud L, Dreyfuss D, Dib F, Massias L, Ricard JD.

Anesthesiology. 2018 Dec;129(6):1140-1148. doi: 10.1097/ALN.0000000000002451.

PMID:
30247201
19.

A randomised, double-blind, placebo-controlled study assessing the efficacy of high doses of vitamin D on functional disability in patients with rheumatoid arthritis.

Soubrier M, Lambert C, Combe B, Gaudin P, Thomas T, Sibilia J, Dougados M, Dubost JJ.

Clin Exp Rheumatol. 2018 Nov-Dec;36(6):1056-1060. Epub 2018 Jul 18.

20.

Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2.

Genovese MC, Combe B, Kremer JM, Tsai TF, Behrens F, Adams DH, Lee C, Kerr L, Nash P.

Rheumatology (Oxford). 2018 Nov 1;57(11):2001-2011. doi: 10.1093/rheumatology/key182.

21.

Risk of fracture and low bone mineral density in adults with inflammatory bowel diseases. A systematic literature review with meta-analysis.

Szafors P, Che H, Barnetche T, Morel J, Gaujoux-Viala C, Combe B, Lukas C.

Osteoporos Int. 2018 Nov;29(11):2389-2397. doi: 10.1007/s00198-018-4586-6. Epub 2018 Jun 16.

PMID:
29909470
22.

Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.

Genovese MC, Fleischmann R, Combe B, Hall S, Rubbert-Roth A, Zhang Y, Zhou Y, Mohamed MF, Meerwein S, Pangan AL.

Lancet. 2018 Jun 23;391(10139):2513-2524. doi: 10.1016/S0140-6736(18)31116-4. Epub 2018 Jun 18.

PMID:
29908670
23.

IL-10 Producing B Cells Ability to Induce Regulatory T Cells Is Maintained in Rheumatoid Arthritis.

Mielle J, Audo R, Hahne M, Macia L, Combe B, Morel J, Daien C.

Front Immunol. 2018 May 3;9:961. doi: 10.3389/fimmu.2018.00961. eCollection 2018.

24.

Relevance and feasibility of a systematic screening of multimorbidities in patients with chronic inflammatory rheumatic diseases.

Daïen CI, Tubery A, Beurai-Weber M, du Cailar G, Picot MC, Jaussent A, Roubille F, Cohen JD, Morel J, Bousquet J, Fesler P, Combe B.

Joint Bone Spine. 2019 Jan;86(1):49-54. doi: 10.1016/j.jbspin.2018.03.016. Epub 2018 Apr 11.

PMID:
29654949
25.

Effects of biologic disease-modifying anti-rheumatic drugs on the radiographic progression of rheumatoid arthritis: a systematic literature review.

Combe B, Lula S, Boone C, Durez P.

Clin Exp Rheumatol. 2018 Jul-Aug;36(4):658-667. Epub 2018 Mar 20. Review.

26.

PhosphoLipid transfer protein (PLTP) exerts a direct pro-inflammatory effect on rheumatoid arthritis (RA) fibroblasts-like-synoviocytes (FLS) independently of its lipid transfer activity.

Audo R, Deckert V, Daien CI, Che H, Elhmioui J, Lemaire S, Pais de Barros JP, Desrumaux C, Combe B, Hahne M, Lagrost L, Morel J.

PLoS One. 2018 Mar 22;13(3):e0193815. doi: 10.1371/journal.pone.0193815. eCollection 2018.

27.

Diabetes at the time of rheumatoid arthritis diagnosis is an independent predictor of pejorative outcomes: Data from the early arthritis ESPOIR cohort.

Daïen CI, Sellam J, Rincheval N, Fautrel B, Saraux A, Morel J, Berenbaum F, Daurès JP, Combe B.

Joint Bone Spine. 2018 Dec;85(6):773-775. doi: 10.1016/j.jbspin.2018.02.004. Epub 2018 Feb 23. No abstract available.

PMID:
29481873
28.

Decreased susceptibility to chlorhexidine affects a quarter of Escherichia coli isolates responsible for pneumonia in ICU patients.

La Combe B, Bleibtreu A, Messika J, Fernandes R, Clermont O, Branger C, Billard-Pomares T, Barnaud G, Magdoud F, Eveillard M, Kouatchet A, Lasocki S, Asfar P, Corvec S, Lakhal K, Armand-Lefevre L, Wolff M, Timsit JF, Bourdon S, Reignier J, Martin S, Fihman V, de Prost N, Bador J, Charles PE, Goret J, Boyer A, Wallet F, Jaillette E, Nseir S, Landraud L, Ruimy R, Danin PE, Dellamonica J, Cremniter J, Frat JP, Jauréguy F, Clec'h C, Decré D, Maury E, Dreyfuss D, Denamur E, Ricard JD.

Intensive Care Med. 2018 Apr;44(4):531-533. doi: 10.1007/s00134-018-5061-8. Epub 2018 Jan 29. No abstract available.

PMID:
29379992
29.

An e-health interactive self-assessment website (Sanoia®) in rheumatoid arthritis. A 12-month randomized controlled trial in 320 patients.

Gossec L, Cantagrel A, Soubrier M, Berthelot JM, Joubert JM, Combe B, Czarlewski W, Wendling D, Dernis E, Grange L, Beauvais C, Perdriger A, Nataf H, Dougados M, Servy H.

Joint Bone Spine. 2018 Dec;85(6):709-714. doi: 10.1016/j.jbspin.2017.11.015. Epub 2017 Dec 12.

30.

Impact of gender on the response and tolerance to abatacept in patients with rheumatoid arthritis: results from the 'ORA' registry.

Nourisson C, Soubrier M, Mulliez A, Baillet A, Bardin T, Cantagrel A, Combe B, Dougados M, Flipo RM, Schaeverbeke T, Sibilia J, Vittecoq O, Ravaud P, Gottenberg JE, Mariette X, Tournadre A.

RMD Open. 2017 Nov 1;3(2):e000515. doi: 10.1136/rmdopen-2017-000515. eCollection 2017.

31.

Response to: 'Cardiovascular effects of hydroxychloroquine: a systematic review and meta-analysis' by Mathieu et al.

Hua C, Rempenault C, Combe B.

Ann Rheum Dis. 2018 Oct;77(10):e66. doi: 10.1136/annrheumdis-2017-212581. Epub 2017 Nov 16. No abstract available.

PMID:
29146738
32.

Response to: 'Metabolic and cardiovascular benefits of hydroxychloroquine: exploration in a wider population at high CV risk' by Pareek et al.

Hua C, Rempenault C, Combe B.

Ann Rheum Dis. 2019 Mar;78(3):e22. doi: 10.1136/annrheumdis-2017-212557. Epub 2017 Nov 1. No abstract available.

PMID:
29092850
33.

Variants of genes implicated in type 1 interferon pathway and B-cell activation modulate the EULAR response to rituximab at 24 weeks in rheumatoid arthritis.

Juge PA, Gazal S, Constantin A, Mariette X, Combe B, Tebib J, Dougados M, Sibilia J, Le Loet X, Dieudé P.

RMD Open. 2017 Sep 28;3(2):e000448. doi: 10.1136/rmdopen-2017-000448. eCollection 2017.

34.

Sodium excretion is higher in patients with rheumatoid arthritis than in matched controls.

Marouen S, du Cailar G, Audo R, Lukas C, Vial G, Tournadre A, Barrat E, Ribstein J, Combe B, Morel J, Daien CI.

PLoS One. 2017 Oct 13;12(10):e0186157. doi: 10.1371/journal.pone.0186157. eCollection 2017.

35.

Chikungunya Virus-Associated Disease.

Hua C, Combe B.

Curr Rheumatol Rep. 2017 Oct 5;19(11):69. doi: 10.1007/s11926-017-0694-0. Review.

PMID:
28983760
36.

Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis.

Rempenault C, Combe B, Barnetche T, Gaujoux-Viala C, Lukas C, Morel J, Hua C.

Ann Rheum Dis. 2018 Jan;77(1):98-103. doi: 10.1136/annrheumdis-2017-211836. Epub 2017 Sep 25. Review.

PMID:
28970215
37.

Risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French Registry REGATE.

Morel J, Constantin A, Baron G, Dernis E, Flipo RM, Rist S, Combe B, Gottenberg JE, Schaeverbeke T, Soubrier M, Vittecoq O, Dougados M, Saraux A, Mariette X, Ravaud P, Sibilia J.

Rheumatology (Oxford). 2017 Oct 1;56(10):1746-1754. doi: 10.1093/rheumatology/kex238.

PMID:
28957557
38.

Poor efficacy of TNF inhibitors in non-radiographic axial spondyloarthritis in the absence of objective signs: A bicentric retrospective study.

Vidal C, Lukas C, Combe B, Berenbaum F, Pers YM, Jorgensen C, Sellam J, Morel J.

Joint Bone Spine. 2018 Jul;85(4):461-468. doi: 10.1016/j.jbspin.2017.08.005. Epub 2017 Sep 14.

PMID:
28917996
39.

Optimal methotrexate dose is associated with better clinical outcomes than non-optimal dose in daily practice: results from the ESPOIR early arthritis cohort.

Gaujoux-Viala C, Rincheval N, Dougados M, Combe B, Fautrel B.

Ann Rheum Dis. 2017 Dec;76(12):2054-2060. doi: 10.1136/annrheumdis-2017-211268. Epub 2017 Sep 2.

PMID:
28866645
40.

Efficacy and safety of biological DMARDs modulating B cells in primary Sjögren's syndrome: Systematic review and meta-analysis.

Letaief H, Lukas C, Barnetche T, Gaujoux-Viala C, Combe B, Morel J.

Joint Bone Spine. 2018 Jan;85(1):15-22. doi: 10.1016/j.jbspin.2017.06.004. Epub 2017 Jun 30.

PMID:
28673789
41.

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.

Nash P, Kirkham B, Okada M, Rahman P, Combe B, Burmester GR, Adams DH, Kerr L, Lee C, Shuler CL, Genovese M; SPIRIT-P2 Study Group.

Lancet. 2017 Jun 10;389(10086):2317-2327. doi: 10.1016/S0140-6736(17)31429-0. Epub 2017 May 24.

PMID:
28551073
42.

Erythroblastopenia in a critically ill influenza patient.

Valainathan SR, Roux D, Almire C, La Combe B.

Intensive Care Med. 2017 Aug;43(8):1150-1151. doi: 10.1007/s00134-017-4839-4. Epub 2017 May 12. No abstract available.

PMID:
28500452
43.

Application of the 2015/2016 EULAR recommendations for cardiovascular risk in daily practice: data from an observational study.

Daïen CI, Tubery A, Cailar GD, Mura T, Roubille F, Morel J, Bousquet J, Fesler P, Combe B.

Ann Rheum Dis. 2018 Apr;77(4):625-626. doi: 10.1136/annrheumdis-2017-211074. Epub 2017 May 6. No abstract available.

PMID:
28478400
44.
45.

Triple Oral Therapy Versus Antitumor Necrosis Factor Plus Methotrexate (MTX) in Patients with Rheumatoid Arthritis and Inadequate Response to MTX: A Systematic Literature Review.

Mary J, De Bandt M, Lukas C, Morel J, Combe B.

J Rheumatol. 2017 Jun;44(6):773-779. doi: 10.3899/jrheum.160643. Epub 2017 Apr 15.

PMID:
28412710
46.

The effect on treatment response of fibromyalgic symptoms in early rheumatoid arthritis patients: results from the ESPOIR cohort.

Durán J, Combe B, Niu J, Rincheval N, Gaujoux-Viala C, Felson DT.

Rheumatology (Oxford). 2017 Jul 1;56(7):1244. doi: 10.1093/rheumatology/kew472. No abstract available.

47.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.

Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, Gottenberg JE, Hazes JMW, Huizinga T, Jani M, Karateev D, Kouloumas M, Kvien T, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Poór G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, van der Heijde D.

Ann Rheum Dis. 2017 Jun;76(6):960-977. doi: 10.1136/annrheumdis-2016-210715. Epub 2017 Mar 6. Review.

48.

Seven-year tolerability profile of glucocorticoids use in early rheumatoid arthritis: data from the ESPOIR cohort.

Roubille C, Rincheval N, Dougados M, Flipo RM, Daurès JP, Combe B.

Ann Rheum Dis. 2017 Nov;76(11):1797-1802. doi: 10.1136/annrheumdis-2016-210135. Epub 2017 Feb 17.

PMID:
28213564
49.
50.

Supplemental Content

Support Center